Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Corbus Pharmaceuticals ( (CRBP) ) is now available.
On September 16, 2025, Corbus Pharmaceuticals announced that the FDA granted Fast Track designation to CRB-701 for treating recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy. This designation, which follows a previous Fast Track for metastatic cervical cancer, aims to expedite the development of CRB-701, a next-generation antibody drug conjugate targeting Nectin-4. The ongoing Phase 1/2 clinical trial is evaluating its safety and efficacy, with dose optimization data to be presented at ESMO 2025, potentially enhancing Corbus’ position in oncology treatment.
The most recent analyst rating on (CRBP) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company based in Norwood, Massachusetts. It focuses on developing innovative scientific approaches to treat serious illnesses, with a pipeline that includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment.
Average Trading Volume: 139,303
Technical Sentiment Signal: Sell
Current Market Cap: $114.8M
For detailed information about CRBP stock, go to TipRanks’ Stock Analysis page.